Acosta Frank L, Sanai Nader, Cloyd Jordan, Deviren Vedat, Chou Dean, Ames Christopher P
Department of Neurological Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
J Spinal Disord Tech. 2011 Jun;24(4):268-75. doi: 10.1097/BSD.0b013e3181efe0a4.
A retrospective review of consecutive series of Enneking stage 3 vertebral hemangiomas surgically treated at a major tertiary spine tumor center.
To determine the short-term recurrence rates, pain improvement, and operative morbidity of intralesional spondylectomy combined with preoperative embolization for Enneking stage 3 vertebral hemangiomas.
Aggressive vertebral hemangiomas (Enneking stage 3) often involve both the anterior and posterior columns with spinal canal and local soft tissue extension and may present with dramatic bony destruction, spinal instability, and pain accompanied with neurologic compromise. Although the current treatment paradigm for most vertebral hemangiomas is conservative management directed toward symptomatic relief, the subset of patients presenting with this rare variant requires more extensive surgical treatment.
A retrospective clinical review of patients diagnosed with Enneking stage 3 vertebral hemangiomas was conducted at the University of California at San Francisco.
We identified 10 consecutive cases of Enneking stage 3 hemangiomas. Average follow-up was 2.42 years. The most common presentation was pain with or without myelopathy. Three of the 10 cases were recurrences after prior partial resection and reconstruction or cement augmentation. All patients underwent preoperative embolization. Average blood loss despite embolization was 2.1 L (range: 0.8 to 5 L). Average preoperative back pain visual analog scale was 7.2 and postoperative visual analog scale was 3.1 at 6 months. On postoperative imaging, all patients had gross total resection. Six patients had staged posterior/anterior transcavitary approach and 4 patients underwent single stage posterior transpedicular spondylectomy. To date, no patient has required adjuvant radiation therapy for tumor recurrence.
Our results suggest that complete wide resection of aggressive Enneking stage 3 lesions can be safely accomplished with acceptable morbidity and blood loss and significant improvement in pain and neurological status. Partial resection of stage 3 lesions, even with stabilization or vertebroplasty, may lead to early recurrence.
对一家大型三级脊柱肿瘤中心手术治疗的连续系列Enneking 3期椎体血管瘤进行回顾性研究。
确定病灶内椎体切除术联合术前栓塞治疗Enneking 3期椎体血管瘤的短期复发率、疼痛改善情况及手术并发症。
侵袭性椎体血管瘤(Enneking 3期)常累及前后柱,伴有椎管及局部软组织受累,可出现明显骨质破坏、脊柱不稳、疼痛并伴有神经功能损害。尽管目前大多数椎体血管瘤的治疗模式是针对症状缓解的保守治疗,但出现这种罕见变异型的患者亚群需要更广泛的手术治疗。
在加利福尼亚大学旧金山分校对诊断为Enneking 3期椎体血管瘤的患者进行回顾性临床研究。
我们确定了10例连续的Enneking 3期血管瘤病例。平均随访时间为2.42年。最常见的表现是伴有或不伴有脊髓病的疼痛。10例中有3例在先前部分切除和重建或骨水泥强化后复发。所有患者均接受了术前栓塞。尽管进行了栓塞,平均失血量仍为2.1升(范围:0.8至5升)。术前平均背痛视觉模拟量表评分为7.2,术后6个月视觉模拟量表评分为3.1。术后影像学检查显示,所有患者均实现了大体全切。6例患者采用分期后/前路经腔入路,4例患者接受了一期后路经椎弓根椎体切除术。迄今为止,尚无患者因肿瘤复发需要辅助放疗。
我们的结果表明,对于侵袭性Enneking 3期病变,可安全地实现完整的广泛切除,并发症和失血量可接受,疼痛和神经状态有显著改善。3期病变即使进行了稳定或椎体成形术的部分切除,也可能导致早期复发。